Sagimet Biosciences Announces Completion of Patient Enrollment in Phase 2b ‘FASCINATE-2’ Clinical Trial with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Non-alcoholic Steatohepatitis

SAN MATEO, Calif.–(BUSINESS WIRE)– #Clinicaltrials–Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced today that it has completed enrollment of its Phase 2b liver biopsy-based clinical trial (“FASCINATE-2”) with denifanstat, a fatty acid synthase (FASN) inhibitor, in non-alcoholic steatohepatitis (NASH) patients. “Completing patient enrollment in…